Low
₹279.75
High
₹329.70
| Previous Close | ₹317.40 |
|---|---|
| Day's Range | ₹279.75 - ₹329.70 |
| Open | ₹281.20 |
| 52 Week Range | ₹233.40 - ₹340.00 |
| Volume | 1,87,11,481 |
| Market Cap | ₹0.01 |
| Previous Close | ₹317.25 |
|---|---|
| Day's Range | ₹281.35 - ₹329.50 |
| Open | ₹281.35 |
| 52 Week Range | ₹230.41 - ₹337.90 |
| Volume | 7,45,941 |
| Market Cap | ₹0.01 |
| Trade Value ( ₹ in Lacs) | 59,473.22 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.06 |
| Price/Earning (TTM) | 55.79 |
| TTM EPS (₹) | 5.69 |
| P/E Ratio | 43.01 |
| Book Value(₹) | 6.38 |
| PAT Margin (%) | 12.95 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 15.70 |
| Trade Value ( ₹ in Lacs) | 2,369.48 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.06 |
| Price/Earning (TTM) | 55.79 |
| TTM EPS (₹) | 5.69 |
| P/E Ratio | 43.01 |
| Book Value(₹) | 6.38 |
| PAT Margin (%) | 12.95 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 15.70 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 3936.29 | 10600.65 |
| Expenses | N/A | N/A |
| PBT | 742.22 | 2463.44 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 574.77 | 1847.02 |
| Founded | 2002 |
|---|---|
| Managing Director | Ankit Thakker |
| NSE Symbol | JLHL |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,52,298.64 | 1,885.10 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,97,324.81 | 11,200.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,78,727.25 | 4,698.80 | 3,672.30 - 3,672.30 |
| Apollo Hospitals Enterprise Ltd. | 1,32,138.82 | 9,190.05 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,29,508.26 | 737.00 | 0.00 - 0.00 |
| Laurus Labs Ltd. | 1,24,001.65 | 2,295.00 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,19,206.70 | 1,195.05 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,16,144.51 | 1,390.50 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,14,312.12 | 1,414.95 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,09,880.22 | 2,660.00 | 1,909.70 - 1,909.70 |
No Records Found
Pursuant to Regulation 30 and Regulation 46(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jupiter Life Line Hospitals has informed that the Audio Link of the Conference Call held today, Monday, October 26, 2026 at 10:00 AM IST for the quarter and half year ended on September 30, 2026 has been made available on the website of the Company at: - jupiterhospital.com/wp-content/uploads/2026/10/Earnings-Call-Audio-Recording-Quarter-2.mp3.
The above information is a part of company’s filings submitted to BSE.
Pursuant to the provisions of Regulation 30 read with Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), FDC has informed that the Company has received an Interim Stay Order from the Hon'ble High Court of Bombay Bench at Aurangabad dated November 20, 2026 staying the Directions of Maharashtra Pollution Control Board (MPCB) directing closure of manufacturing operations of the Company’s unit situated at Plot no. B-8, MIDC, Waluj, Chhatrapati Sambhajinagar under the Water (Prevention and Control of Pollution) Act, 1974 and/or the Air (Prevention and Control of Pollution) Act, 1981, and the rules framed thereunder. The Company had already submitted to MPCB its Compliance Reports on their observations. The requisite disclosure as required under Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular Ref. No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure I.
The above information is a part of company’s filings submitted to BSE.
In continuation to earlier letter Ref. No.P-66/2026-27/55 dated 16th November, 2026 respectively, 3B BlackBio Dx has informed that the Company interacted one to one with Fortuna Asset Managers LLP, Delhi on Saturday, 21th November, 2026 at 12:00 hrs India Time. The meeting concluded at 13:00 hrs India Time. The information which is already available in public domain was discussed and no unpublished price sensitive information pertaining to the company was shared with the investor. During this investor meeting, the company reiterated the information shared by it through Investor Presentation of Q2-FY27, which was earlier intimated to the Stock Exchanges vide Ref. No.P66/2026-27/53 dated 13th November, 2026. The company has enclosed the web link of the presentation placed before investors after the declaration of the financial results for the quarter and half year ended 30-09-2026 and the above-mentioned investor.
No Records Found
The current share price of Jupiter Life Line Hospitals Ltd. is ₹317.40 as of 2026-11-20.
The market capitalisation of Jupiter Life Line Hospitals Ltd. is ₹10,400.41 as of 2026-11-20.
The 1-year return of Jupiter Life Line Hospitals Ltd. is 23.22% as of 2026-11-20.
The P/E ratio of Jupiter Life Line Hospitals Ltd. is 43.01 as of 2026-11-21.
The 52-week high and low of Jupiter Life Line Hospitals Ltd. are ₹340.00 and ₹233.40, respectively, as of 2026-11-20.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.